Skip to main content
. 2022 Apr 4;146(4):279–288. doi: 10.1161/CIRCULATIONAHA.122.059725

Figure 3.

Figure 3.

Effects of empagliflozin vs placebo on KCCQ-TSS at day 90 across prespecified subgroups. AF indicates atrial fibrillation; eGFR, estimated glomerular filtration rate; HF, heart failure; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire-Total Symptom Score; LVEF, left ventricular ejection fraction; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.